Dr Heather Jorgensen

  • Research Fellow (Paul O'Gorman Leukaemia Research Centre)

telephone: 0141 301 7875
email: Heather.Jorgensen@glasgow.ac.uk

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Targeting CD70/27 axis in TKI treated BCR-ABL1+ CML cells with ARGX-110
    Cancer Research UK
    2016 - 2017
     
  • Proof of principle: sLDL can deliver drugs to proliferating CLL cells within the bone marrow niche in vivo to reduce tumour burden
    Cancer Research UK
    2012 - 2013
     
  • Investigation of synthetic low-density lipoprotein (sLDL) as a novel drug delivery system to overcome chemoresistance of proliferating CLL cells.
    British Society for Haematology
    2011 - 2012
     
  • Development of biomarkers for induction and inhibition of autophagy in TKI treated CML patients
    Novartis
    2011 - 2013
     
  • Targeting proliferating CLL cells with a novel drug delivery system
    Cancer Research UK
    2010 - 2012
     
  • Development of a flow cytometry service within the Paul O'Gorman Leukaemia Research Centre
    The Kay Kendall Leukaemia Fund
    2010 - 2013
     
  • The relevance of autocrine growth factor activation to the survival and proliferation of primitive chronic myeloid leukaemia (CML) cells.
    Medical Research Council
    2010 - 2013
     
  • Leukaemia stem cell biology
    William Thyne Centenary Fellowship
    2009 - 2010
     
  • Effect of major efflux transporters on the intracellular concentration of dasatinib in CML CD34+ patient cells and cell lines
    Tenovus Scotland
    2009 - 2009
     
  • The Characterisation of and Novel Therapies to eradicate cancer stem cells in chronic myeloid leukaemia
    Dr Rhona Reid Charitable Trust
    2007 - 2010
     
  • Measurement and modulation of tyrosine kinase inhibitor drug levels in chronic myeloid leukaemia.
    Scottish Executive Health Department
    2007 - 2008
     
  • G-CSF intermittently with imatinib mesylate may eradicate residual leukaemic stem cells in Chronic Myeloid Leukaemia
    North Glasgow University Hospitals NHS Trust
    2004 - 2005
     
  • A Study of the frequency & reversibility of & strategies to eradicate Quiescent Leukaemia Stem Cells in Chronic Myeloid Leukaemia
    The Kay Kendall Leukaemia Fund
    2002 - 2005
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001
Number of items: 57.

2018

Toofan, P., Busch, C., Morrison, H., O'Brien, S., Jørgensen, H., Copland, M. and Wheadon, H. (2018) Chronic myeloid leukemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Cell Death and Disease, 9, 927. (doi:10.1038/s41419-018-0905-2) (PMID:30206237) (PMCID:PMC6134087)

Hayatigolkhatmi, K. et al. (2018) Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells. Blood Cells, Molecules, and Diseases, 69, pp. 119-122. (doi:10.1016/j.bcmd.2017.11.002) (PMID:29217295)

2017

Ganugula, R. et al. (2017) Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic ß-cells for effective management of type 1 diabetes mellitus. British Journal of Pharmacology, 174(13), pp. 2074-2084. (doi:10.1111/bph.13816) (PMID:28409821)

Ben Batalla, I. et al. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23(9), pp. 2289-2300. (doi:10.1158/1078-0432.CCR-16-1930) (PMID:27856601)

Tarafdar, A. et al. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129(2), pp. 199-208. (doi:10.1182/blood-2016-09-742049) (PMID:27793879) (PMCID:PMC5305055)

Jackson, L. , Gómez-Castañeda, E., Jørgensen, H. G., Hopcroft, L. E.M. , Rogers, S. , Holyoake, T. L. and Huang, X. (2017) Oncogene addiction in chronic myeloid leukaemia. In: eLS. John Wiley & Sons, Ltd, pp. 1-9. ISBN 9780470015902 (doi:10.1002/9780470015902.a0024464)

2016

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi:10.1158/2159-8290.CD-16-0263) (PMID:27630125)

Laidlaw, K. M.E. et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 7(32), pp. 51651-51664. (doi:10.18632/oncotarget.10541) (PMID:27438151)

Gómez-Castañeda, E., Hopcroft, L.E.M. , Rogers, S. , Jorgensen, H.G., Pellicano, F., Vetrie, D. , Copland, M. , Grimmond, S. and Holyoake, T.L. (2016) Uncovering the BCR-ABL1 Tyrosine Kinase Independent Signature in Chronic Myeloid Leukaemia Stem Cells. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. (doi:10.1111/bjh.14019)

Jackson, L., Hopcroft, L.E.M. , Rogers, S. , Jorgensen, H., Pellicano, F., Wells, C., Mosbergen, R., Chen, T., Vetrie, D. and Holyoake, T.L. (2016) Identifying Genes and Pathways Deregulated in Chronic Myeloid Leukaemia Stem Cells Through Meta-Analysis of Transcriptomic Data. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. (doi:10.1111/bjh.14019)

Michie, A.M. , Tarafdar, A., Gallipoli, P., Pellicano, F., Hopcroft, L. , Korfi, K., Cassels, J., Jorgensen, H.J., Vetrie, D. and Holyoake, T.L. (2016) CML Cells Actively Evade Host Immune Surveillance Through Cytokine-Mediated Downregulation of MHC-I I Expression. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. (doi:10.1111/bjh.14019)

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L. , Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L. and Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, 128(23), pp. 2671-2682. (doi:10.1182/blood-2015-11-679928) (PMID:27621307) (PMCID:PMC5146743)

2015

Venkatpurwar, V.P., Rhodes, S. , Oien, K.A., Elliott, M.A., Tekwe, C.D., Jorgensen, H.G. and Ravi Kumar, M.N.V. (2015) Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter. Toxicology, 330, pp. 9-18. (doi:10.1016/j.tox.2015.01.017) (PMID:25637670)

2014

Gallipoli, P., Cook, A., Rhodes, S. , Hopcroft, L. , Wheadon, H. , Whetton, A. D., Jorgensen, H. G., Bhatia, R. and Holyoake, T. L. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood, 124(9), pp. 1492-1501. (doi:10.1182/blood-2013-12-545640) (PMID:24957147) (PMCID:PMC4148771)

Crawford, L.J., Chan, E.T., Aujay, M., Holyoake, T., Melo, J.V., Jorgensen, H., Suresh, S., Walker, B. and Irvine, A.E. (2014) Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis, 3(3), e90. (doi:10.1038/oncsis.2014.3) (PMID:24590311) (PMCID:PMC3940921)

2013

Scott, M. T. et al. (2013) Misregulation of the PRC2 Complex in CML Stem Cells Confers Sensitivity to an EZH2 Inhibitor. American Society of Hematology 55th Annual Meeting, New Orleans, LA, USA, 7-10 Dec 2013.

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M. , Jorgensen, H.G. and Holyoake, T.L. (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 122(19), pp. 3335-3339. (doi:10.1182/blood-2013-02-485607)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

2012

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G. and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26(5), pp. 545-547. (doi:10.1002/bmc.1686)

MacKay, C.E., Allen, E.K., Mukhopadhyay, A., Karvela, M., Holyoake, T., Jorgensen, H. and Helgason, V. (2012) Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells. British Journal of Haematology, 157(S1), p. 58. (doi:10.1111/j.1365-2141.2012.09071.x)

Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L. and Jorgensen, H. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 48(3), pp. 199-201. (doi:10.1016/j.bcmd.2012.01.005)

Gallipoli, P., Jorgensen, H. and Holyoake, T.L. (2012) Modulation of TGF-β 1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells. British Journal of Haematology, 157(S1), pp. 55-56. (doi:10.1111/j.1365-2141.2012.09071.x)

Roy, S., Jorgensen, H.G., Roy, P., Abed El Baky, M., Melo, J.V., Strathdee, G., Holyoake, T.L. and Bartholomew, C. (2012) BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. British Journal of Haematology, 157(4), pp. 446-456. (doi:10.1111/j.1365-2141.2012.09078.x)

2011

Allan, E.K., Holyoake, T.L., Craig, A.R. and Jorgensen, H.G. (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia, 25(6), pp. 985-994. (doi:10.1038/leu.2011.55)

Iqbal, Z., Elliott, M., Watson, D.G., Holyoake, T.L. and Jorgensen, H.G. (2011) Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. Pakistan Journal of Pharmaceutical Sciences, 24(3), pp. 285-291.

2010

Zhou, P., Hatziieremia, S., Elliott, M. A., Scobie, L., Crossan, C., Michie, A. M. , Holyoake, T. L., Halbert, G. W. and Jorgensen, H. G. (2010) Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy. Journal of Controlled Release, 148(3), pp. 380-387. (doi:10.1016/j.jconrel.2010.09.016)

Heaney, N. B. et al. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115(11), pp. 2241-2250. (doi:10.1182/blood-2008-06-164582)

Jiang, X. et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 116(12), pp. 2112-2121. (doi:10.1182/blood-2009-05-222471)

2009

Pellicano, F., Copland, M. , Jorgensen, H. G., Mountford, J., Leber, B. and Holyoake, T. L. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114(19), pp. 4186-4196. (doi:10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23(11), pp. 1999-2006. (doi:10.1038/leu.2009.166)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C. and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37(6), pp. 692-700. (doi:10.1016/j.exphem.2009.02.006)

Allan, E.K., Hamilton, A., Hatziieremia, S., Zhou, P., Jorgensen, H.G., Vigneri, P. and Holyoake, T.L. (2009) Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia, 23(5), pp. 1006-1008. (doi:10.1038/leu.2008.367)

Hamilton, A., Alhashimi, F., Myssina, S., Jorgensen, H. G. and Holyoake, T. L. (2009) Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 37(3), pp. 395-401. (doi:10.1016/j.exphem.2008.11.005)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi:10.1016/j.exphem.2008.10.013)

2007

Jorgensen, H.G. and Holyoake, T.L. (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochemical Society Transactions, 35(5), pp. 1347-1351. (doi:10.1042/BST0351347)

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi:10.1158/1078-0432.CCR-07-0919)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G. and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109(9), pp. 4016-4019. (doi:10.1182/blood-2006-11-057521)

2006

Allan, E.K., Holyoake, T.L. and Jorgensen, H.G. (2006) Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemia. Leukemia, 20(11), pp. 2054-2055. (doi:10.1038/sj.leu.2404411)

Holyoake, T.L., Jordanides, N., Jorgensen, H.G. and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108(4), pp. 1370-1373. (doi:10.1182/blood-2006-02-003145)

Hamilton, A., Elrick, L., Myssina, S., Copland, M. , Jorgensen, H.G., Melo, J.V. and Holyoake, T.L. (2006) BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia, 20(6), pp. 1035-1039. (doi:10.1038/sj.leu.2404189)

Jorgensen, H.G., Copland, M. , Allan, E.K., Jiang, X.Y., Eaves, A., Eaves, C. and Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12(2), pp. 626-633. (doi:10.1158/1078-0432.CCR-05-0429)

2005

Copland, M. , Jorgensen, H.G. and Holyoake, T.L. (2005) Evolving molecular therapy for chronic myeloid leukaemia - are we on target? Hematology, 10(5), pp. 349-359. (doi:10.1080/10245330500234195)

Jorgensen, H.G., Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A. and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33(10), pp. 1140-1146. (doi:10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C. and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi:10.1038/sj.leu.2403785)

Jorgensen, H.G., McLellan, S., Crossan, J. and Curtis, A.S.G. (2005) Neutralisation of TGFβ or binding of VLA-4 to fibronectin prevents rat tendon adhesion following transection. Cytokine, 30(4), pp. 195-202. (doi:10.1016/j.cyto.2004.12.017)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G. and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105(5), pp. 1862-1866. (doi:10.1182/blood-2004-08-3373)

Jorgensen, H.G., Copland, M. and Holyoake, T. (2005) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer, 103(1), pp. 210-211. (doi:10.1002/cncr.20742)

Curtis, A.S.G., Wilkinson, C.D.W., Crossan, J., Broadley, C., Darmani, H., Johal, K.K., Jorgensen, H. and Monaghan, W. (2005) An in vivo microfabricated scaffold for tendon repair. European Cells and Materials, 9, pp. 50-57.

Jorgensen, H.G. and Holyoake, T.L. (2005) From paradigm to paradox, ponder anew the CML stem cell. Bloodmed Com,

2003

Jorgensen, H.G., Allan, E.K., Jiang, X., Liakopoulou, E., Richmond, L., Eaves, C.J., Eaves, A.C. and Holyoake, T.L. (2003) Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia. Leukemia, 17(7), pp. 1430-1432. (doi:10.1038/sj.leu.2402967)

Paterson, S.C., Smith, K.D., Holyoake, T.L. and Jorgensen, H.G. (2003) Is there a cloud in the silver lining for imatinib? British Journal of Cancer, 88(7), pp. 983-987. (doi:10.1038/sj.bjc.6600828)

Clark, A.D., Jorgensen, H.G., Mountford, J.C. and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41(2-3), pp. 111-131. (doi:10.1023/A:1024822722285)

2002

Jorgensen, H.G., Elliott, M., Paterson, S., Holyoake, T.L. and Smith, K. (2002) Further observations on the debated ability of AGP to bind imatinib - Response. Blood, 100(1), pp. 368-369.

Graham, S.M., Jorgensen, H.G., Allan, E.K., Pearson, C., Alcorn, M.J., Richmond, L. and Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99(1), pp. 319-325. (doi:10.1182/blood.V99.1.319)

Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L. and Smith, K.D. (2002) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99(2), pp. 713-715. (doi:10.1182/blood.V99.2.713)

2001

Jorgensen, H.G. and Holyoake, T.L. (2001) A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematological Oncology, 19(3), pp. 89-106. (doi:10.1002/hon.667.abs)

Holyoake, T.L., Jiang, X.Y., Jorgensen, H.G., Graham, S., Alcorn, M.J., Laird, C., Eaves, A.C. and Eaves, C.J. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97(3), pp. 720-728. (doi:10.1182/blood.V97.3.720)

This list was generated on Sat Dec 15 14:29:39 2018 GMT.
Number of items: 57.

Articles

Toofan, P., Busch, C., Morrison, H., O'Brien, S., Jørgensen, H., Copland, M. and Wheadon, H. (2018) Chronic myeloid leukemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Cell Death and Disease, 9, 927. (doi:10.1038/s41419-018-0905-2) (PMID:30206237) (PMCID:PMC6134087)

Hayatigolkhatmi, K. et al. (2018) Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells. Blood Cells, Molecules, and Diseases, 69, pp. 119-122. (doi:10.1016/j.bcmd.2017.11.002) (PMID:29217295)

Ganugula, R. et al. (2017) Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic ß-cells for effective management of type 1 diabetes mellitus. British Journal of Pharmacology, 174(13), pp. 2074-2084. (doi:10.1111/bph.13816) (PMID:28409821)

Ben Batalla, I. et al. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23(9), pp. 2289-2300. (doi:10.1158/1078-0432.CCR-16-1930) (PMID:27856601)

Tarafdar, A. et al. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129(2), pp. 199-208. (doi:10.1182/blood-2016-09-742049) (PMID:27793879) (PMCID:PMC5305055)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi:10.1158/2159-8290.CD-16-0263) (PMID:27630125)

Laidlaw, K. M.E. et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 7(32), pp. 51651-51664. (doi:10.18632/oncotarget.10541) (PMID:27438151)

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L. , Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L. and Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, 128(23), pp. 2671-2682. (doi:10.1182/blood-2015-11-679928) (PMID:27621307) (PMCID:PMC5146743)

Venkatpurwar, V.P., Rhodes, S. , Oien, K.A., Elliott, M.A., Tekwe, C.D., Jorgensen, H.G. and Ravi Kumar, M.N.V. (2015) Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter. Toxicology, 330, pp. 9-18. (doi:10.1016/j.tox.2015.01.017) (PMID:25637670)

Gallipoli, P., Cook, A., Rhodes, S. , Hopcroft, L. , Wheadon, H. , Whetton, A. D., Jorgensen, H. G., Bhatia, R. and Holyoake, T. L. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood, 124(9), pp. 1492-1501. (doi:10.1182/blood-2013-12-545640) (PMID:24957147) (PMCID:PMC4148771)

Crawford, L.J., Chan, E.T., Aujay, M., Holyoake, T., Melo, J.V., Jorgensen, H., Suresh, S., Walker, B. and Irvine, A.E. (2014) Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis, 3(3), e90. (doi:10.1038/oncsis.2014.3) (PMID:24590311) (PMCID:PMC3940921)

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M. , Jorgensen, H.G. and Holyoake, T.L. (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 122(19), pp. 3335-3339. (doi:10.1182/blood-2013-02-485607)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G. and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26(5), pp. 545-547. (doi:10.1002/bmc.1686)

MacKay, C.E., Allen, E.K., Mukhopadhyay, A., Karvela, M., Holyoake, T., Jorgensen, H. and Helgason, V. (2012) Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells. British Journal of Haematology, 157(S1), p. 58. (doi:10.1111/j.1365-2141.2012.09071.x)

Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L. and Jorgensen, H. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 48(3), pp. 199-201. (doi:10.1016/j.bcmd.2012.01.005)

Gallipoli, P., Jorgensen, H. and Holyoake, T.L. (2012) Modulation of TGF-β 1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells. British Journal of Haematology, 157(S1), pp. 55-56. (doi:10.1111/j.1365-2141.2012.09071.x)

Roy, S., Jorgensen, H.G., Roy, P., Abed El Baky, M., Melo, J.V., Strathdee, G., Holyoake, T.L. and Bartholomew, C. (2012) BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. British Journal of Haematology, 157(4), pp. 446-456. (doi:10.1111/j.1365-2141.2012.09078.x)

Allan, E.K., Holyoake, T.L., Craig, A.R. and Jorgensen, H.G. (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia, 25(6), pp. 985-994. (doi:10.1038/leu.2011.55)

Iqbal, Z., Elliott, M., Watson, D.G., Holyoake, T.L. and Jorgensen, H.G. (2011) Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. Pakistan Journal of Pharmaceutical Sciences, 24(3), pp. 285-291.

Zhou, P., Hatziieremia, S., Elliott, M. A., Scobie, L., Crossan, C., Michie, A. M. , Holyoake, T. L., Halbert, G. W. and Jorgensen, H. G. (2010) Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy. Journal of Controlled Release, 148(3), pp. 380-387. (doi:10.1016/j.jconrel.2010.09.016)

Heaney, N. B. et al. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115(11), pp. 2241-2250. (doi:10.1182/blood-2008-06-164582)

Jiang, X. et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 116(12), pp. 2112-2121. (doi:10.1182/blood-2009-05-222471)

Pellicano, F., Copland, M. , Jorgensen, H. G., Mountford, J., Leber, B. and Holyoake, T. L. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114(19), pp. 4186-4196. (doi:10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23(11), pp. 1999-2006. (doi:10.1038/leu.2009.166)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C. and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37(6), pp. 692-700. (doi:10.1016/j.exphem.2009.02.006)

Allan, E.K., Hamilton, A., Hatziieremia, S., Zhou, P., Jorgensen, H.G., Vigneri, P. and Holyoake, T.L. (2009) Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia, 23(5), pp. 1006-1008. (doi:10.1038/leu.2008.367)

Hamilton, A., Alhashimi, F., Myssina, S., Jorgensen, H. G. and Holyoake, T. L. (2009) Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 37(3), pp. 395-401. (doi:10.1016/j.exphem.2008.11.005)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi:10.1016/j.exphem.2008.10.013)

Jorgensen, H.G. and Holyoake, T.L. (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochemical Society Transactions, 35(5), pp. 1347-1351. (doi:10.1042/BST0351347)

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi:10.1158/1078-0432.CCR-07-0919)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G. and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109(9), pp. 4016-4019. (doi:10.1182/blood-2006-11-057521)

Allan, E.K., Holyoake, T.L. and Jorgensen, H.G. (2006) Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemia. Leukemia, 20(11), pp. 2054-2055. (doi:10.1038/sj.leu.2404411)

Holyoake, T.L., Jordanides, N., Jorgensen, H.G. and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108(4), pp. 1370-1373. (doi:10.1182/blood-2006-02-003145)

Hamilton, A., Elrick, L., Myssina, S., Copland, M. , Jorgensen, H.G., Melo, J.V. and Holyoake, T.L. (2006) BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia, 20(6), pp. 1035-1039. (doi:10.1038/sj.leu.2404189)

Jorgensen, H.G., Copland, M. , Allan, E.K., Jiang, X.Y., Eaves, A., Eaves, C. and Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12(2), pp. 626-633. (doi:10.1158/1078-0432.CCR-05-0429)

Copland, M. , Jorgensen, H.G. and Holyoake, T.L. (2005) Evolving molecular therapy for chronic myeloid leukaemia - are we on target? Hematology, 10(5), pp. 349-359. (doi:10.1080/10245330500234195)

Jorgensen, H.G., Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A. and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33(10), pp. 1140-1146. (doi:10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C. and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi:10.1038/sj.leu.2403785)

Jorgensen, H.G., McLellan, S., Crossan, J. and Curtis, A.S.G. (2005) Neutralisation of TGFβ or binding of VLA-4 to fibronectin prevents rat tendon adhesion following transection. Cytokine, 30(4), pp. 195-202. (doi:10.1016/j.cyto.2004.12.017)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G. and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105(5), pp. 1862-1866. (doi:10.1182/blood-2004-08-3373)

Jorgensen, H.G., Copland, M. and Holyoake, T. (2005) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer, 103(1), pp. 210-211. (doi:10.1002/cncr.20742)

Curtis, A.S.G., Wilkinson, C.D.W., Crossan, J., Broadley, C., Darmani, H., Johal, K.K., Jorgensen, H. and Monaghan, W. (2005) An in vivo microfabricated scaffold for tendon repair. European Cells and Materials, 9, pp. 50-57.

Jorgensen, H.G. and Holyoake, T.L. (2005) From paradigm to paradox, ponder anew the CML stem cell. Bloodmed Com,

Jorgensen, H.G., Allan, E.K., Jiang, X., Liakopoulou, E., Richmond, L., Eaves, C.J., Eaves, A.C. and Holyoake, T.L. (2003) Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia. Leukemia, 17(7), pp. 1430-1432. (doi:10.1038/sj.leu.2402967)

Paterson, S.C., Smith, K.D., Holyoake, T.L. and Jorgensen, H.G. (2003) Is there a cloud in the silver lining for imatinib? British Journal of Cancer, 88(7), pp. 983-987. (doi:10.1038/sj.bjc.6600828)

Clark, A.D., Jorgensen, H.G., Mountford, J.C. and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41(2-3), pp. 111-131. (doi:10.1023/A:1024822722285)

Jorgensen, H.G., Elliott, M., Paterson, S., Holyoake, T.L. and Smith, K. (2002) Further observations on the debated ability of AGP to bind imatinib - Response. Blood, 100(1), pp. 368-369.

Graham, S.M., Jorgensen, H.G., Allan, E.K., Pearson, C., Alcorn, M.J., Richmond, L. and Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99(1), pp. 319-325. (doi:10.1182/blood.V99.1.319)

Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L. and Smith, K.D. (2002) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99(2), pp. 713-715. (doi:10.1182/blood.V99.2.713)

Jorgensen, H.G. and Holyoake, T.L. (2001) A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematological Oncology, 19(3), pp. 89-106. (doi:10.1002/hon.667.abs)

Holyoake, T.L., Jiang, X.Y., Jorgensen, H.G., Graham, S., Alcorn, M.J., Laird, C., Eaves, A.C. and Eaves, C.J. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97(3), pp. 720-728. (doi:10.1182/blood.V97.3.720)

Book Sections

Jackson, L. , Gómez-Castañeda, E., Jørgensen, H. G., Hopcroft, L. E.M. , Rogers, S. , Holyoake, T. L. and Huang, X. (2017) Oncogene addiction in chronic myeloid leukaemia. In: eLS. John Wiley & Sons, Ltd, pp. 1-9. ISBN 9780470015902 (doi:10.1002/9780470015902.a0024464)

Conference or Workshop Item

Gómez-Castañeda, E., Hopcroft, L.E.M. , Rogers, S. , Jorgensen, H.G., Pellicano, F., Vetrie, D. , Copland, M. , Grimmond, S. and Holyoake, T.L. (2016) Uncovering the BCR-ABL1 Tyrosine Kinase Independent Signature in Chronic Myeloid Leukaemia Stem Cells. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. (doi:10.1111/bjh.14019)

Jackson, L., Hopcroft, L.E.M. , Rogers, S. , Jorgensen, H., Pellicano, F., Wells, C., Mosbergen, R., Chen, T., Vetrie, D. and Holyoake, T.L. (2016) Identifying Genes and Pathways Deregulated in Chronic Myeloid Leukaemia Stem Cells Through Meta-Analysis of Transcriptomic Data. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. (doi:10.1111/bjh.14019)

Michie, A.M. , Tarafdar, A., Gallipoli, P., Pellicano, F., Hopcroft, L. , Korfi, K., Cassels, J., Jorgensen, H.J., Vetrie, D. and Holyoake, T.L. (2016) CML Cells Actively Evade Host Immune Surveillance Through Cytokine-Mediated Downregulation of MHC-I I Expression. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. (doi:10.1111/bjh.14019)

Scott, M. T. et al. (2013) Misregulation of the PRC2 Complex in CML Stem Cells Confers Sensitivity to an EZH2 Inhibitor. American Society of Hematology 55th Annual Meeting, New Orleans, LA, USA, 7-10 Dec 2013.

This list was generated on Sat Dec 15 14:29:39 2018 GMT.